Botswana Combination Prevention Project (BCPP)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01965470|
Recruitment Status : Unknown
Verified July 2016 by Centers for Disease Control and Prevention.
Recruitment status was: Enrolling by invitation
First Posted : October 18, 2013
Last Update Posted : October 10, 2018
|Condition or disease||Intervention/treatment||Phase|
|HIV||Other: Combination Prevention Other: Enhanced Care||Phase 4|
|Study Type :||Interventional (Clinical Trial)|
|Intervention Model:||Parallel Assignment|
|Official Title:||Botswana Combination Prevention Project: -Evaluation Protocol (Protocol #1): Research Design and Impact Evaluation -Closed Clinical Cohort Protocol (Protocol #3) Implementation, Monitoring and Evaluation of Combination HIV Prevention Interventions in Rural and Peri-Urban Communities in Botswana|
|Actual Study Start Date :||October 30, 2013|
|Estimated Primary Completion Date :||October 2018|
Experimental: Combination Prevention
Other: Combination Prevention
Active Comparator: Enhanced Care
Enhanced Care Communities will receive guidance and improved technical support for quality management and data systems at all local clinics at which individuals receive HIV care and treatment.
Other: Enhanced Care
- Population-level, cumulative HIV incidence [ Time Frame: 3 years ]Population-level cumulative HIV incidence will be measured in a cohort of HIV-negative persons identified from a 20% sample of eligible households in the 30 study communities followed annually.
- 2. Population-level uptake of HIV testing and counseling (HTC), ART, VL Suppression, male circumcision (MC), and PMTCT services [ Time Frame: 3 years ]Population-level uptake of each intervention will be measured in an annual survey of the 20% sample of eligible households in the 30 study communities and through analysis of routine program monitoring data.
- Cost per additional infection averted [ Time Frame: 3 years ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01965470
|Botswana communities and Botswana Ministry of Health clinics|
|Multiple Locations, Multiple, Botswana|
|Principal Investigator:||Janet S Moore, PhD||Centers for Disease Control and Prevention|
|Principal Investigator:||Myron Essex, DVM, PhD||Harvard School of Public Health|
|Principal Investigator:||Refeletswe Lebelonyane, MD||Botswana Ministry of Health|
|Principal Investigator:||Shenaaz El Halabi, MPH||Botswana Ministry of Health|
|Principal Investigator:||Joseph Makhema, MBChB, FRCP||Botswana Harvard Aids Institute|
|Principal Investigator:||Shahin Lockman, MD, MS||Harvard T.H. Chan School of Public Health|
|Principal Investigator:||Eric Tchetgen Tchetgen, PhD||Harvard T.H. Chan School of Public Health|
|Principal Investigator:||Molly Pretorius Holme, MS||Harvard T.H. Chan School of Public Health|
|Principal Investigator:||Pam Bachanas, PhD||Centers for Disease Control and Prevention|
|Principal Investigator:||Tafireyi Marukutira, MD||Centers for Disease Control and Prevention|